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Background: The clinical effect of bisphosphonate treatment has not been clearly evaluated by kidney function in
Japanese Chronic Kidney Disease (CKD) patients with osteoporosis. This study analyzed the data from three risedronate
Japanese phase III trials. The clinical effect of risedronate therapy was evaluated in CKD patients with osteoporosis.
Methods: The Japanese clinical trials involved 852 subjects who received risedronate (2.5 mg once daily or 17.5 mg
once weekly) and whose estimated glomerular filtration rate (eGFR) were calculable and at≥ 30 mL/min. The subjects
were divided into subgroups according to the eGFR level: ≥ 90 mL/min/1.73 m2, ≥ 60 to < 90 mL/min/1.73 m2, ≥ 30
to < 60 mL/min/1.73 m2. Lumbar spine bone mineral density (BMD), bone turnover markers (BTMs) and adverse events
were evaluated at 48 weeks.
Results: Adverse event incidence was similar among three subgroups. There was also no exacerbation of impaired
kidney function associated with risedronate administration in the subjects with eGFR above 30 mL/min/1.73 m2.
Risedronate administration induced a significant increase in lumbar spine BMD and significant inhibition of BTMs in
three subgroups.
Conclusions: The risedronate therapy showed similar clinical effects in CKD patients with osteoporosis compared to
those without CKD.
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There is an overlap in the age of onset of chronic kidney
disease (CKD) and osteoporosis. The incidence of these
diseases increases proportionally with age. Age is the
main factor affecting kidney function. The glomerular
filtration rate (GFR), an index of kidney function,
decreases linearly with age [1]. The elderly account for a
large proportion of osteoporosis patients, many of whom
also have CKD. It is therefore important to consider
kidney function in patients with osteoporosis. Klawansky
et al. examined the relationship between age, kidney* Correspondence: taki@wakayama-med.ac.jp
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with osteoporosis and reported impaired kidney function
in 85% of the female subjects and 58% of the male sub-
jects [2]. Numerous clinical trials on bisphosphonates
have been conducted, although they have excluded
patients with impaired kidney function based on serum
creatinine levels. Therefore there is only a limited
amount of information on the safety and efficacy of
bisphosphonate treatment in patients with impaired
kidney function or kidney failure [3–5].
Risedronate is a pyridyl compound and a third gener-
ation bisphosphonate. It has been demonstrated to be
effective for treating osteoporosis [5–11]. In the Japanese
population, risedronate has been shown to be an effect-
ive treatment as an oral dose of 2.5 mg once daily,
17.5 mg once weekly, and 75 mg once monthly [6–9]. Inle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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age used outside of Japan (5 mg once daily, 35 mg once
weekly) [12]. The plasma concentrations of risedronate
after the administration of 2.5 mg risedronate to the
Japanese population were nearly comparable to the
serum concentrations after the administration of 5 mg
risedronate to the UK study population. The difference
in oral bisphosphonate dosages between Japanese and
subjects outside Japan suggested a difference in bioavail-
ability between Japanese and non-Japanese individuals,
although the reasons for this difference remain unknown
[13]. As a consequence these doses of risedronate have
been approved and can be used clinically. In our study,
data from Japanese phase III clinical trials of risedronate
were analyzed. The study evaluated the safety and effi-
cacy of risedronate in Japanese osteoporosis patients
who were divided into subgroups according to the level
of estimated GFR (eGFR): ≥ 90 mL/min/1.73 m2, ≥ 60
to < 90 mL/min/1.73 m2, ≥ 30 to < 60 mL/min/1.73 m2.
Methods
Study design
This study analyzed data from three phase III multicenter,
randomized, double-blind, controlled trials (CCT-003,
CCT-005, and CCT-101). The objective of CCT-003 and
CCT-101 trial was to demonstrate the non-inferiority of
2.5 mg daily risedronate to etidronate, the non-inferiority
of 17.5 mg weekly risedronate to 2.5 mg daily risedronate
on BMD of the lumbar spine, respectively, while the
objective of CCT-005 trial was to demonstrate the non-
inferiority of 2.5 mg daily risedronate to etidronate on
incidence of vertebral fracture. These trials were con-
ducted in Japan from March 1999 to July 2004 [6–8].
The analysis was performed on the data from 887
osteoporosis patients who were assigned to a group
receiving risedronate whose dose and administration
period varied by trial (Fig. 1).
Patients
The subjects were of either sex and were patients with
involutional osteoporosis based on the diagnostic criteria
for primary osteoporosis established by the Japanese
Society for Bone and Mineral Research (JSBMR) [14,
15]. Primary osteoporosis was defined by the presence of
a fragility fracture and BMD < 80% of the ‘young adult
mean’ (20 to 44 years of age), or BMD < 70% of the
‘young adult mean’ in the absence of a detectable fragil-
ity fracture [15]. The subjects were aged between 40 and
75 years (inclusive) in the CCT-003 trial, at least 50 years
in the CCT-005 and CCT-101 trial. The trial period was
48 weeks in the CCT-003 trial, 96 weeks in the CCT-005
trial, and 48 weeks in the CCT-101 trial. In the CCT-003
and CCT-005 trials, the eligible patients were randomized
to receive either treatment with 2.5 mg of risedronateonce daily (risedronate 2.5 mg group) or intermittent
treatment with etidronate (one cycle: 2 weeks of 200 mg
once daily followed by 10 weeks off) (cyclic intermittent
etidronate group). In the CCT-101 trial, the eligible
patients were assigned randomly to either treatment with
2.5 mg of risedronate once daily (risedronate 2.5 mg
group) or treatment with 17.5 mg of risedronate once
weekly (risedronate 17.5 mg group). Weekly dosing with
17.5 mg risedronate was well tolerated in Japanese osteo-
porotic patients, and showed equivalent efficacy to daily
dosing with 2.5 mg risedronate [8]. In each trial, all the
patients received oral 1.54 g of calcium lactate (200 mg of
calcium daily) during the trial period as a supplement for
dietary calcium deficiency. The daily dose of calcium was
based on the result of the National Nutrition Survey
conducted by the Ministry of Health, Labor, and Welfare
(recommended daily allowance of calcium for Japanese,
600 mg; actual intake, 585 mg on average in 1995) and on
determination of the necessary amount in the elderly, esti-
mated in a calcium balance study (700–800 mg) [16]. The
exclusion criteria included patients with any of the follow-
ing conditions: secondary osteoporosis, disease other than
secondary osteoporosis that causes bone loss, findings that
affect BMD measurement of the lumbar spine, a history of
oral bisphosphonate use within one year of trial com-
mencement, use of oral risedronate, use of any drug affect-
ing bone metabolism (vitamin D3 and vitamin K2
preparations, and calcitonin analogs, etc.) within eight
weeks of trial commencement, severe renal, hepatic, or
cardiac impairment, gastrointestinal impairment, predis-
position to drug hypersensitivity, current use of an anti-
cancer drug for malignant tumor treatment, or a history of
radiation therapy in the lumbar spine or pelvic region. Dur-
ing the trial period, the patients were prohibited from
concurrent use of any drug affecting bone metabolism.
In our study, the analyses were performed according to
kidney function level assessed using eGFR. An equation
derived from serum creatinine levels of the Japanese
population was used to calculate eGFR. The baseline
eGFR value of each patient was calculated, and the pa-
tients then divided into eGFR subgroups according to the
criteria of the Japanese Society of Nephrology [17, 18]: ≥
90 mL/min/1.73 m2, ≥ 60 to < 90 mL/min/1.73 m2, ≥ 30
to < 60 mL/min/1.73 m2.
Endpoints
The following indices were evaluated using comprehensive
data from the three trials: percentage change in lumbar
spine BMD relative to baseline and the effects on bone re-
sorption markers (urine N-terminal telopeptide of type 1
collagen (NTX) and urine C-terminal telopeptide of type 1
collagen (CTX)) and bone formation marker (serum bone-
specific alkaline phosphatase (BAP)). In the CCT-003 and
CCT-101 trials, BMD measurements were made for
Fig. 1 Disposition of subjects
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ometry (DXA) system (QDR, XR, or DPX type). The BMD
of each patient at each time point were measured using the
same DXA system. The measurements were made at trial
commencement and 12, 24, 36, and 48 weeks. If the sub-
jects discontinued the trial, the measurements were made
at the time of withdrawal.
Safety was evaluated based on the adverse events and
change from baseline in kidney function and Calcium/
Phosphorus. All adverse events were collected prospect-
ively starting with the first dose of risedronate. Even
events that were initially reported by a subject was diag-
nosed and monitored by investigators. The incidence of
overall adverse events, adverse events associated with
kidney, urinary, gastrointestinal disorders, osteonecrosis
of the jaw and atypical femoral fractures, were analyzed.Statistical analyses
The mean ± standard deviation (SD) values of the follow-
ing variables were calculated for each subgroup: age and
body mass index (BMI) at baseline; and eGFR, serum cre-
atinine, calcium, phosphorus, bone turnover markers
(urine NTX, urine CTX, and serum BAP) and lumbar
spine BMD for each time point. We conducted linear
mixed effect model analyses on the efficacy and safety
endpoints collected sequentially. The mixed models in-
cluded subgroup, time, and interaction of subgroup and
time as fixed effects, and the subjects as a random effect.
The incidence and number of subjects with adverse events
were also obtained for each subgroup. We performed the
F test for numerical variables and chi-square test for nom-
inal variables in baseline characteristics, and Fisher’s exacttest for adverse events. The statistical analyses were per-
formed using SAS version 9.3 (Cary, NC, USA).
Results
Patient disposition
A total of 887 eligible patients were randomized to
receive risedronate (CCT-003 trial, n = 118: CCT-005
trial, n = 273; and CCT-101 trial, n = 496). The dose and
administration period varied in the three trials, although
the subjects were not subdivided according to these
characteristics in our study. Of the eligible patients, two
patients in the CCT-101 trial were excluded because the
study drug was not administered. Of the remaining 885
patients, 852 patients had an eGFR that was calculable
and at ≥ 30 mL/min, and had their kidney function eval-
uated (Fig. 1). These 852 patients were the subjects in
our study.
The baseline characteristics of the subjects are shown
in Table 1 (eGFR ≥ 90 mL/min/1.73 m2 group; 99 sub-
jects (11.6%), ≥ 60 to < 90 mL/min/1.73 m2 group; 525
subjects (61.6%), ≥ 30 to < 60 mL/min/1.73 m2 group;
228 subjects (26.8%), respectively). There were statisti-
cally significantly differences among the subgroups in
age, daily/weekly, body mass index (BMI).
Efficacy: BMD and bone turnover markers
All subgroups showed a significant increase in lumbar
spine BMD and a significant inhibition of bone turnover
markers (urine NTX, urine CTX, and serum BAP) after
48 weeks of risedronate administration (Figs. 2 and 3).
The interactions between time and subgroups were not
significant on inhibition of bone turnover markers
(NTX; p = 0.0759, CTX; p = 0.3183, BAP; p = 0.7064),
Table 1 Baseline characteristics of subjects
Overall eGFR (mL/min/1.73 m2)
≧90 ≧60 to <90 ≧30 to <60 P value
Number of subjects 852 99 525 228
Age (years) 68.6 ± 8.1 63.7 ± 7.4 68.0 ± 7.7 72.1 ± 7.7 <0.0001*
Sex (male/female) 32/820 5/94 21/504 6/222 0.5110**
Daily/Weekly 604/248 63/36 350/175 191/37 <0.0001**
BMI (kg/m2) 22.2 ± 3.1 21.3 ± 2.8 22.0 ± 2.9 22.9 ± 3.3 <0.0001*
Lumbar spine BMD (g/cm2) 0.67 ± 0.09 0.67 ± 0.08 0.67 ± 0.09 0.67 ± 0.08 0.7043*
Values are mean ± SD
*F test, **Chi square test
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BMD percent change from baseline at 48 weeks among
subgroups were not significant (p = 0.5835).eGFR, Serum creatinine, calcium, and phosphorus
The interactions between time and subgroups were
not significant on calcium (p = 0.1129) and phos-
phorus (p = 0.1041), but eGFR (p < 0.0001) and
creatinine (p < 0.0001) (Table 2).Safety
There was also no difference between subgroups in the
incidence of overall adverse events, adverse events asso-
ciated with gastrointestinal disorders, or urinary- and
kidney function-related adverse events (Table 3). In
addition, there were no reported cases of osteonecrosis
of the jaw and atypical femoral fracture.Fig. 2 Mean percent change (± SD) from baseline in lumbar spine BMD in
eGFR in baseline, and the mean percent change in lumbar spine BMD in eDiscussion
In the present study, we have found that treatment with
risedronate in Japanese osteoporosis patients irrespective
of the level of eGFR was effective.
In this study, there were some differences among the
subgroups (Table 1). But these differences were consid-
ered clinically insignificant. Because age was included in
the calculation formula for eGFR, differences in age
among the subgroups was not unusual. This relationship
was also observed in other studies [19, 20]. The efficacy
and safety were similar between daily dosing with
2.5 mg risedronate and weekly dosing with 17.5 mg rise-
dronate [8]. Therefore the difference did not affect the
current evaluation. BMI values were within the normal
range (18.5-25.0 kg/m2), and did not indicate obesity.
Based on other studies, risedronate is a safe and ef-
fective drug for the treatment and prevention of
osteoporosis [5–11]. But, similar to other bisphospho-
nates, risedronate is excreted through the kidneys. Itreceiving risedronate. Patients were stratified into three cohorts by
ach cohort was shown. *p < 0.001, significantly different from baseline
ab
c
Fig. 3 Mean percent change (± SD) from baseline in bone turnover
markers (Urine NTX (a), Urine CTX (b) and Serum BAP (c)) in receiving
risedronate. Patients were stratified into three cohorts by eGFR in
baseline, and the mean percent change in bone turnover markers in
each cohort was shown. *p < 0.001, significantly different from baseline
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with kidney insufficiency [19]. Therefore, the effect of
renal insufficiency on the safety and efficacy of rise-
dronate treatment is an important consideration in
clinical practice. There was a report about the safety
and efficacy of risedronate in the osteoporosis patient
including eGFR < 30 ml/min [19], but there is noreport about Japanese patients. In Japan, the package
insert of risedronate states that it is contraindicated
in patients with severe kidney insufficiency (creatinine
clearance of less than approximately 30 mL/min).
Other bisphosphonates are also carefully administered,
and bisphosphonates should therefore be administered
carefully in patients with kidney insufficiency. In our
study, changes from baseline in eGFR and serum
creatinine after 48 weeks of treatment were observed.
The chronological changes in eGFR and creatinine
measurements observed in this study are thought to
be due to regression to the mean (phenomenon in
which variables used at varied distributions at baseline
or sub-group means for variables that are strongly
correlated to such variables will approach the overall
mean at next measurement) rather than risedronate
administration, and when we took into consideration
the fact that the changes from baseline were small, we
concluded that these changes were clinically insignificant.
The changes in serum calcium and phosphorus were small
and there were no significant differences. Miller et al.
found that although there were sporadic statistically sig-
nificant differences between the treatment groups with
respect to the mean percent changes from baseline in
serum calcium and serum phosphorus, these differences
were small and an expected consequence of changes in
calcium homeostasis caused by inhibition of bone resorp-
tion during therapy. They were therefore not considered
to be clinically meaningful [19]. Yanik et al. conducted a
trial on women with osteoporosis or osteopenia and
reported that blood urea nitrogen, serum creatinine, and
eGFR did not change from baseline following 12 months
of risedronate treatment [21]. These results are also con-
sistent with ours.
We found that there was no difference in the incidence
of overall adverse events, adverse events associated with
gastrointestinal disorders, or urinary- and kidney function-
related adverse events among the subgroups regardless of
the level of eGFR. Our findings are consistent with subse-
quently published analyses [19, 20]. Miller et al. reported
that there was no difference in the incidence of overall
adverse events or renal-related events of risedronate treat-
ment by eGFR, Jamal et al. also reported that there was no
difference in the frequency of gastrointestinal events in
women with reduced renal function (4.5%) compared with
those without (5.2%; p = 0.5), and renal adverse events in
women with reduced renal function (2.1%) compared with
those without (2.3%; p = 0.68).
Kaji et al. found a higher rate of vertebral fracture in
postmenopausal women at CKD stage 3 or greater com-
pared with those at stage 1 or 2. They also examined the
relationship between creatinine clearance and vertebral
fracture in CKD stage 2 postmenopausal women using
logistic regression analysis with adjustment for years
Table 2 Mean change from baseline in kidney function and Calcium/Phosphorus and the results of the test of the fixed effects by
the linear mixed effect model analyses
eGFR (mL/min/1.73 m2)
≧90 ≧60 to < 90 ≧30 to < 60
N Mean SD N Mean SD N Mean SD
eGFR (mL/min/1.73 m2) Baseline 99 99.19 9.56 525 72.12 7.98 228 50.74 6.54
12 weeks 94 91.84 15.90 498 70.77 10.92 209 54.43 10.43
24 weeks 89 88.89 12.24 482 70.74 11.26 201 54.64 10.41
36 weeks 86 91.22 13.91 455 71.75 11.65 184 55.54 10.59
48 weeks 84 93.04 14.08 441 72.11 11.95 177 55.06 11.48
subgroup P < 0.0001
time P < 0.0001
interaction of the subgroup and time P < 0.0001
Creatinine (mg/dL) Baseline 99 0.48 0.05 525 0.64 0.07 228 0.86 0.12
12 weeks 94 0.53 0.09 498 0.65 0.10 209 0.82 0.16
24 weeks 89 0.54 0.08 482 0.65 0.10 201 0.82 0.16
36 weeks 86 0.53 0.09 455 0.65 0.10 184 0.81 0.15
48 weeks 84 0.52 0.08 441 0.64 0.11 177 0.82 0.17
subgroup P < 0.0001
time P = 0.0178
interaction of the subgroup and time P < 0.0001
Calcium (mg/dL) Baseline 99 9.15 0.37 525 9.08 0.41 228 9.05 0.40
12 weeks 83 9.10 0.39 387 9.10 0.38 115 9.07 0.41
24 weeks 88 9.13 0.36 481 9.12 0.41 198 9.07 0.40
36 weeks 79 9.11 0.40 356 9.17 0.41 111 9.21 0.37
48 weeks 83 9.14 0.35 441 9.13 0.41 182 9.09 0.44
subgroup P = 0.4597
time P < 0.0001
interaction of the subgroup and time P = 0.1129
Phosphorus (mg/dL) Baseline 26 3.52 0.34 187 3.36 0.47 146 3.43 0.52
12 weeks 14 3.48 0.43 59 3.29 0.49 36 3.36 0.45
24 weeks 22 3.28 0.46 162 3.22 0.55 119 3.31 0.48
36 weeks 14 3.14 0.36 51 3.14 0.48 34 3.31 0.60
48 weeks 20 3.44 0.45 146 3.32 0.48 109 3.35 0.51
subgroup P = 0.0888
time P < 0.0001
interaction of the subgroup and time P = 0.1041
The linear mixed models included subgroup, time, and interaction of subgroup and time as fixed effects, and the subjects as a random effect
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clearance level was shown to be associated with the risk
of vertebral fracture in these women [22]. Therefore,
treatment for osteoporosis is important in patients who
also have CKD [4]. In Japanese osteoporosis patients
with decreased kidney function, evaluation by kidney
function has not always been performed when investi-
gating the safety and efficacy of drugs used to treat
osteoporosis, despite the clinical importance of thesecharacteristics. Our data are important because Japanese
osteoporosis patients have been shown to have some
degree of kidney impairment, and there is currently little
published information about the effect of risedronate
treatment in patients with kidney insufficiency. The
results of our study showed that lumbar spine BMD
increased and bone turnover markers (urine NTX, urine
CTX, and serum BAP) were inhibited regardless of kidney
function after 48 weeks of risedronate administration.
Table 3 Summary of adverse events
eGFR (mL/min/1.73 m2)
≧90 ≧60 to <90 ≧30 to <60 P value
Number of subjects 99 525 228
All adverse events 82 (82.8%) 462 (88.0%) 198 (86.8%) 0.3609*
gastrointestinal symptoms–relate adverse events 33 (33.3%) 192 (36.6%) 88 (38.6%) 0.6631*
Abdominal pain upper 4 (4.0%) 31 (5.9%) 7 (3.1%) NT
Constipation 4 (4.0%) 37 (7.0%) 19 (8.3%) NT
Diarrhoea 4 (4.0%) 17 (3.2%) 12 (5.3%) NT
Stomach discomfort 11 (11.1%) 44 (8.4%) 14 (6.1%) NT
Urinary- and kidney function-related adverse events 2 (2.0%) 11 (2.1%) 7 (3.1%) 0.6295*
Osteonecrosis of the jaw 0 (0.0%) 0 (0.0%) 0 (0.0%) NT
Atypical femoral fractures 0 (0.0%) 0 (0.0%) 0 (0.0%) NT
NT not test
* Fisher’s exact test
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the increase in lumbar spine BMD or decrease in bone
turnover markers among these subgroups. In a study con-
ducted outside of Japan, Miller et al. evaluated compre-
hensive data from nine risedronate phase III studies and
examined the safety and effect of the drug on kidney func-
tion in osteoporosis patients (severe kidney impairment:
creatinine clearance (CrCl) < 30 mL/min, moderate kidney
impairment: CrCl > 30 to < 50 mL/min, and mild kidney
impairment: CrCl > 50 to < 80 mL/min). Lumbar spine
BMD increased significantly and the incidence of new ver-
tebral fractures decreased significantly in the group receiv-
ing risedronate (regardless of kidney function) compared
with the group receiving placebo [19]. They also reported
that comparison of the placebo group and subgroups
receiving risedronate showed all subgroups had a greater
reduction in bone turnover marker levels (serum BAP and
urine deoxypyridinoline levels) relative to baseline levels.
These results of Miller et al. were consistent with our
results.
There were some limitations in this study. First, in
this study did not include data on bisphosphonate ad-
ministration in osteoporosis patients with kidney func-
tion of eGFR < 30 mL/min/1.73 m2. Further studies are
therefore necessary. Second, this was a post hoc ana-
lysis of pooled data from 3 trials, which were originally
neither intended to determine the influence of kidney
function nor randomized for the level of eGFR. Third,
this study did not analyze the samples with the
intention to treat, and excluded some patients. Fourth,
this study did not assess the effect of risedronate on hip
BMD, and did not evaluate the anti-hip fracture efficacy
of risedronate due to lack of data. Finally, this study
only investigated a 48 weeks period. Adverse events
such as osteonecrosis of the jaw and atypical fractures
are likely to require long-term observation, whichmeans that this study was not able to sufficiently exam-
ine for these adverse events.
Conclusions
In our study, the data from Japanese phase III trials
conducted on osteoporosis patients was analyzed. The
results showed that risedronate therapy has similar clin-
ical effects in CKD patients with osteoporosis compared
to those without CKD.
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